The following antibodies were used: anti-integrin α6 (BD Biosciences, Franklin Lakes, NJ, USA, Cat. # 555734); anti-GM130 (IF: Cell Signaling Technology, Danvers, MA, USA, Cat. # 12480S; IHC: Novus Biologicals, Littleton, CO, USA, Cat. # NBP1-89756); anti-human CK 14 (Thermo Fisher, Waltham, MA, USA, Cat. # MA5-11599); anti-human CK 18 (Thermo Fisher, Waltham, MA, USA, Cat. # PA514263); anti-mouse CK 14 (BioLegend, San Diego, CA, USA, Cat. # 905301); anti-mouse CK 8/18 (DSHB, Iowa City, IA, USA, Cat. # Troma-I); anti-alpha smooth muscle actin (Abcam, Cambridge, UK, Cat. # Ab7817); anti-E-cadherin (BD Biosciences, Franklin Lakes, NJ, USA, Cat. # 610182); anti-vimentin (Life Technologies, Carlsbad, CA, USA, Cat. # PA5-86264); anti-PAR3 (Millipore, Burlington, MA, USA, Cat. # 07-330); anti-laminin alpha3 (Novus Biologicals, Littleton, CO, USA, Cat. # CL3112); and phospho-SMAD3 antibody (pS423/pS425, Novus Biologicals, Littleton, CO, USA, Cat. # NBP1-77836SS).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.